<DOC>
	<DOCNO>NCT00850382</DOCNO>
	<brief_summary>This Phase Ib/IIa open-labeled multi-center trial evaluate feasibility dasatinib give standard induction therapy daunorubicin ( DNR ) cytarabine ( ARA-C ) , consolidation therapy high-dose cytarabine ( HDAC ) , single agent one-year maintenance therapy patient newly diagnose CBF AML . 82 patient newly diagnose CBF AML enrol AMLSG study center . All AML patient assess CBF fusion gene via central laboratory AMLSG within 48 hour diagnosis AML , patient CBF AML enrol study .</brief_summary>
	<brief_title>Dasatinib ( Sprycel™ ) Patients With Newly Diagnosed Core Binding Factor ( CBF ) Acute Myeloid Leukemia ( AML )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Core binding factor ( CBF ) AML molecular diagnosis RUNX1RUNX1T1 fusion transcript result ( 8 ; 21 ) ( q22 ; q22 ) ( variant form ) CBFBMYH11 fusion transcript result inv ( 16 ) ( p13.1q22 ) /t ( 16 ; 16 ) ( p13.1 ; q22 ) assess one central AMLSG reference laboratory . Age ≥ 18 ; upper age limit . No prior chemotherapy leukemia except hydroxyurea 5 day diagnostic screening phase . Nonpregnant nonnursing . Due unknown teratogenic potential dasatinib human , pregnant nursing patient may enrol . Women childbearing potential ( WOCBP ) must negative serum urine pregnancy test within sensitivity least 25 mIU/mL within 72 hour prior registration . Women childbearing potential must either commit continued abstinence heterosexual intercourse begin TWO acceptable method birth control one highly effective method ( e.g. , IUD , hormonal , tubal ligation , partner 's vasectomy ) , one additional effective method ( e.g. , latex condom , diaphragm , cervical cap ) AT THE SAME TIME , least four week begin dasatinib therapy . `` Women childbearing potential '' define sexually active mature woman undergone hysterectomy menses time precede 24 consecutive month . Men must agree father child must use latex condom sexual contact woman childbearing potential take dasatinib 4 week therapy stop , even undergone successful vasectomy . Signed write informed consent Performance status WHO &gt; 2 Pulmonary edema and/or pleural/pericardial effusion within 14 day Day 1 . If edema/effusion resolve CTC Grade ≤ 1 , patient treat dasatinib . Patients ejection fraction &lt; 50 % echocardiography within 14 day day 1 Organ insufficiency ( creatinine &gt; 1.5x upper normal serum level ; bilirubin , AST AP &gt; 2.5x upper normal serum level ; heart failure NYHA III/IV ; severe obstructive restrictive ventilation disorder ) Uncontrolled infection Severe neurological psychiatric disorder interfere ability give informed consent Known positive HIV Bleeding disorder independent leukemia No consent registration , storage process individual diseasecharacteristics course</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>CBF AML</keyword>
	<keyword>Dasatinib</keyword>
	<keyword>Core Binding Factor ( CBF )</keyword>
</DOC>